Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Integumen Debt Conversion

1 May 2019 11:00

RNS Number : 7356X
Venn Life Sciences Holdings PLC
01 May 2019
 

1 May 2019

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Integumen plc ("Integumen") Debt Conversion - Related Party Transaction

Venn Life Sciences, an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations, announces, that following the approval of Integumen shareholders and under the terms of the Venn Debt Conversion Agreement the debt of £421,000 owed by Integumen, has been converted into 30,071,428 new Integumen ordinary shares at a price of 1.4 pence, conditional upon admission.

Separate to this conversion, Venn has sold 42,244,682 ordinary shares for a total consideration of €575,000. Following Admission of the conversion shares referred to above, Venn will hold 30,071,428 ordinary shares.

Venn has agreed that any disposal of Integumen ordinary shares held by them for the two years following Admission will be effected through Integumens broker so as to ensure an orderly market in the ordinary shares.

The debt conversion is a related party transaction for the purposes of Rule 13 of the AIM Rules for companies. As Tony Richardson is Integumens Chairman, the Chief Executive of Venn, and therefore is not considered to be independent for the purposes of considering and negotiating the Venn Debt Conversion Agreement. The Directors (other than Tony Richardson) consider, having consulted with Arden Partners plc, the Company's nominated adviser, that the terms of the Venn Debt Conversion Agreement and conversion by Venn are fair and reasonable in so far as its Shareholders are concerned.

 

Enquiries:

Venn Life Sciences Holdings plc Tel: +353 1 5499 341Tony Richardson, Chief Executive Officer

Arden Partners plc Tel: +44 (0)2076145900

John Llewellyn-Lloyd, Ruari McGirr, Benjamin Cryer

Davy (ESM Adviser and Joint Broker) Tel: +353 (0)1 679 6363Fergal Meegan / Matthew de Vere White (Corporate Finance)

 

 

DEFINITIONS

The following words and expressions shall have the following meanings in this document unless the context otherwise requires:

 

"Venn Debt Conversion Agreement"

the agreement dated 11 April 2019 between (1) the Company and (2) Venn to convert the Venn Debt into the Venn Debt Shares

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCSSASUFFUSEEI
Date   Source Headline
28th Sep 20167:00 amRNSHalf-year Report
22nd Sep 20167:00 amRNSAppointment of Non Executive Director
13th Sep 20167:00 amRNSDirectorate Change
24th Aug 20167:00 amRNSNotice of Results
3rd Aug 20167:00 amRNSContract wins
30th Jun 201612:18 pmRNSResult of AGM
30th Jun 20167:00 amRNSAGM Statement
20th Jun 20164:24 pmRNSShareholder notification
10th Jun 201611:05 amRNSPosting of Annual Report and Notice of AGM
10th May 20167:00 amRNSFinal Results
24th Mar 20167:00 amRNSYear End Update
18th Jan 20168:00 amRNSEnterprise Securities Market Notice
13th Jan 20167:00 amRNSESM Schedule 1 update
13th Jan 20167:00 amRNSESM Appendix to Schedule 1 update
12th Jan 20167:00 amRNSContracts worth EUR 3.4m signed with US Biotech
8th Jan 20162:03 pmRNSHolding(s) in Company
8th Jan 20167:01 amRNSTrading update
8th Jan 20167:00 amRNSDirectorate Change
11th Dec 20157:00 amRNSChange of Adviser
11th Dec 20157:00 amRNSESM Pre-Admission Announcement
11th Dec 20157:00 amRNSAppendix to Schedule 1 announcement
3rd Nov 20157:00 amRNSGrant of Share Option & Total Voting Rights
23rd Oct 20157:00 amRNSContract for over EUR1m with French Biotech
19th Oct 20157:00 amRNSAppointment of Director
19th Oct 20157:00 amRNSCompletion of the Acquisition of Kinesis Pharma BV
9th Oct 201511:38 amRNSResult of General Meeting & Update on Acquisition
22nd Sep 20157:01 amRNSHalf Yearly Report
22nd Sep 20157:00 amRNSProposed acquisition & Placing
24th Aug 20152:00 pmRNSAppointment of Co-Broker
21st Aug 20157:00 amRNSNotice of Results
13th Aug 20157:00 amRNSTrading update
30th Jun 201511:39 amRNSResult of AGM
30th Jun 20157:00 amRNSAGM Statement
15th Jun 20157:00 amRNSAppointment of Chief Financial Officer
10th Jun 20153:46 pmRNSEUR 2m contract with leading European biotech
28th May 201510:14 amRNSPosting of Annual Report & Notice of AGM
22nd May 20157:00 amRNSFinal Results
20th May 20153:29 pmRNSHolding(s) in Company
20th May 20157:00 amRNSNew services from Innovenn
12th May 20157:01 amRNSDirectorate Change
8th Apr 20159:06 amRNSHolding(s) in Company
8th Apr 20159:05 amRNSHolding(s) in Company
7th Apr 20152:39 pmRNSHolding(s) in Company
7th Apr 201511:17 amRNSHolding(s) in Company
2nd Apr 20152:00 pmRNSInvestor teach-in
2nd Apr 20157:00 amRNSInnoVenn expands products and first sales in US
1st Apr 201512:14 pmRNSResult of General Meeting
30th Mar 20157:00 amRNSContracts for EUR4.1m with US Biotech client
13th Mar 20154:45 pmRNSPlacing to raise £2 million
6th Mar 20157:00 amRNSChange of Registered Office

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.